June 17, 2020

To Whom It May Concern

NanoCarrier Co., Ltd.
Tetsuhito Matsuyama, President & CEO
(Code No. 4571)

Primary Endpoint Achieved in Phase IIa portion of NC-6004 Phase II Clinical Study in Combination with Keytruda for Head and Neck Cancer

NanoCarrier is pleased to announce that the primary endpoint of Phase IIa portion (to establish NC-6004 recommended dose in conjunction with pembrolizumab) was achieved. NC-6004-009 study is being conducted in the US and European countries in combination with pembrolizumab for head and neck cancer.

Good tolerability as well as anti-tumor activity was observed in Phase IIa portion. The preliminary result will be presented at Controlled Release Society Virtual Annual Meeting which will be held between June 29, 2020 to July 2, 2020. Controlled Release Society is a renowned scientific organization specialized in drug delivery. Dr. Kazunori Kataoka who is a scientific advisor of NanoCarrier has been involved in 2020 Program Committee of Controlled Release Society.

NanoCarrier has been pursuing clinical trial initiation activity with health authorities in each target country towards Phase IIb portion.

[Outline of the Phase IIb clinical study]
Target indication: Head and neck cancer
(Recurrent/metastatic head and neck squamous cell carcinoma previously treated with platinum agents)
Planned number of subjects: 124 (62 and 62)
Primary endpoints: Comparison of the median progression-free survival (PFS) between NC-6004 in combination with Keytruda and Keytruda alone
Study duration: Approximately 2 years

NanoCarrier expects that micellar nanoparticles, including NC-6004, will help to improve the value of preparations in the anti-cancer drug market, while agents such as its platform technology will have no impact on earnings for the fiscal year ending March 2021.

Contact: info@nanocarrier.co.jp